Sorafenib-induced pancreatitis

Year 2015, Volume: 32 Issue: 3, 133 - 135, 17.11.2015

Talat Ayyıldız , Taner Aydın Ahmet Tarık Eminler , Çınar Yıldırım Kader Irak Murat Kıyıcı Selim Gürel Selim Giray Nak Macit Gülten Enver Dolar

https://izlik.org/JA97AL88ZM

Abstract

Sorafenib is an inhibitor of multikinase proteins which is used for metastatic renal cell carcinoma and advanced stage hepatocellular carcinoma. Its side effects include serum amylase and lipase elevations anticipated to occur within first weeks of treatment but clinically and radiologically evident acute pancreatitis develops rarely. Five cases of acute pancreatitis have been reported in literature until date. The case we described here is the sixth case of clinically diagnosed acute pancreatitis.

Keywords

Hepatocellular carcinoma , Pancreatitis , Sorafenib , Tyrosine kinase inhibitor

References

• Amar et al. Li and Srinivas Saadati and Saif Kobayashi et al. Sevin et al. 69 Female Metastatic renal cell carcinoma Dose of Sorafenib 400 mg twice daily 400 mg twice daily Not reported 400 mg twice daily 400 mg twice daily 3 weeks 4 weeks Not reported 2 weeks 10 days 1014 244
• Fig. A cross-section from the abdominal computed tomography scan of the patient after developing pancreatitis 135 weeks and all of them resolved spontaneously. Additionally, there were no clinical or radiological findings which were suggestive of pancreatitis (Hyodo et al., 2012).
• Pancreatic ischemia at the earlier phase of acute pancreatitis is important for development of pancreatic necrosis. Possible mechanisms contributing to the process include chemical-induced vasoconstriction, direct damage to vessel wall, intravascular coagulation and increased endothelial permeability (Klar et al., 1990). Mitogen
• Activated Protein Kinase (MAPK) is a downstream effector of Ras/Raf/MEK/ERK pathway and found to be activated in acute pancreatitis (Murr et al., 2003). A marked elevation in serum VEGF level was noted in patients with acute pancreatitis but its association with the severity or prognosis of the disease could not be established (Ueda et al., 2006).
• Child, C.G.III., Turcotte, J.G., 1964. Surgery and portal hypertension. In: The liver and portal hypertension, Child, C.G., Eds, W.B. Saunders, Philadelphia. P.50.
• Hyodo, I., Adachi, M., Tsukamoto, T., Murai, M., Naito, S., Akaza, H., 2012. Serum pancreatic enzyme elevation under treatment with sorafenib.
• Gan. To. Kagaku. Ryoho. 39, 1651-1656.
• Klar, E., Messmer, K., Warshaw, A.L., Herfarth, C., 1990. Pancreatic ischaemia in experimental acute pancreatitis: Mechanism, significance and therapy. Br. J. Surg. 77, 1205-1210.
• Kobayashi, Y., Kanemitu, T., Kamoto, A., Satoh, M., Mori, N., Sekii, K., Yoshioka, T., Itatani, H., Fujimoto, T., 2011. Painless acute pancreatitis associated with sorafenib treatment: A case report. Med. Oncol. 28, 463-465. doi: 10.1007/s12032-010-9479-2.
• Li, M., Srinivas, S., 2007. Acute pancreatitis associated with sorafenib. South Med. J. 100, 909-911.
• Murr, M.M., Yang, J., Fier, A., Gallagher, S.F., Carter, G., Gower, W.R. Jr., Norman, J.G., 2003. Regulation of kupffer cell TNF gene expression during experimental acute pancreatitis: The role of p38-MAPK, ERK1/2, SAPK/JNK, and NF-kappaB. J. Gastrointest. Surg. 7, 20-25.
• Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R., 1973. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646-649.
• Saadati, H., Saif, M.W., 2010. Sorafenib-induced acute pancreatitis. JOP. 11, 283-284.
• Sevin, A., Chen, A., Atkinson, B., 2013. Tyrosine kinase inhibitor induced pancreatitis. J. Oncol. Pharm. Pract. 19, 257-260. doi: 1177/1078155212457968.
• Ueda, T., Takeyama, Y., Yasuda, T., Matsumura, N., Sawa, H., Nakajima, Kuroda, Y., 2006. Vascular endothelial growth factor increases in serum and protects against the organ injuries in severe acute pancreatitis. J. Surg. Res. 134, 223-230. doi:10.1016/j.jss.2005.12.032.